MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Revenue
$7,670K
Net Income
-$131,005K
Net Profit Margin
-1708.02%
EPS
-$0.25
Unit: Thousand (K) dollars
Revenue Breakdown
License And Service
Grant
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Total revenue
7,670
6,472
35,538
5,175
Cost of revenue
11,491
12,490
14,276
14,687
Research and development
89,614
87,896
95,939
121,062
General and administrative
41,533
34,591
33,658
41,628
Total operating costs and expenses
142,638
134,977
143,873
177,377
Loss from operations
-134,968
-128,505
-108,335
-172,202
Other income (loss), net
3,962
6,397
232
9,952
Loss before income tax benefit
-131,006
-122,108
-108,103
-162,250
Income tax benefit
-1
-4,604
19
3
Net loss
-131,005
-117,504
-108,122
-162,253
Basic EPS
-0.25
-0.22
-0.207
-0.36
Diluted EPS
-0.25
-0.22
-0.207
-0.36
Basic Average Shares
532,460,085
529,303,984
522,663,271
446,988,046
Diluted Average Shares
532,460,085
529,303,984
522,663,271
446,988,046
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Net loss
-$131,005K
(23.79%↑ Y/Y)
Income tax benefit
-$1K
Loss before income
tax benefit
-$131,006K
(23.79%↑ Y/Y)
Other income (loss),
net
$3,962K
(-8.50%↓ Y/Y)
License And Service
$7,303K
(-61.77%↓ Y/Y)
Grant
$367K
(205.83%↑ Y/Y)
Loss from operations
-$134,968K
(23.41%↑ Y/Y)
Total revenue
$7,670K
(-60.10%↓ Y/Y)
Total operating costs
and expenses
$142,638K
(-27.02%↓ Y/Y)
Research and development
$89,614K
(-30.34%↓ Y/Y)
General and
administrative
$41,533K
(-10.97%↓ Y/Y)
Cost of revenue
$11,491K
(-43.00%↓ Y/Y)
Buy us a coffee
6556d670e8da976dc91d11c4_Recursion Logo Horizontal Black-svg
RECURSION PHARMACEUTICALS, INC. (RXRX)
6556d670e8da976dc91d11c4_Recursion Logo Horizontal Black-svg
RECURSION PHARMACEUTICALS, INC. (RXRX)